TNF Pharmaceuticals, Inc. – NASDAQ:TNFA

TNF Pharmaceuticals stock price today

$0.1
-1.14
-91.97%
Financial Health
0
1
2
3
4
5
6
7
8
9

TNF Pharmaceuticals key metrics

Market Cap
 3.71M
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 N/A
Revenue
 N/A
EBITDA
 N/A
Income
 N/A
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

TNF Pharmaceuticals stock price history

TNF Pharmaceuticals stock forecast

TNF Pharmaceuticals financial statements

Profit Margin

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA): Profit margin
2015 2.11M -9.31M -440.27%
2017 3.35M -7.36M -219.58%
2020 0 -17.58M
2023 0 -3.99M
TNFA income statement history
0%
Yield TTM
TNF Pharmaceuticals, Inc. (NASDAQ:TNFA): Payout ratio
Payout ratio 0%
TNF Pharmaceuticals, Inc. (NASDAQ:TNFA): Dividend Yield
2019
2020
2021
2022
2023 49.29%
TNFA dividends history

Debt to Assets

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA): Debt to assets
2014 16650872 1.84M 11.07%
2015 8271909 1.66M 20.17%
2017 9337890 1.78M 19.12%
2023 17862270 5.08M 28.49%
TNFA balance sheet history

Cash Flow

TNF Pharmaceuticals, Inc. (NASDAQ:TNFA): Cash Flow
2017 -5.08M -5.01M 10.46M
2019 -3.07M -3.94M 6.96M
2022 -12.27M 6.91M 5.55M
2023 -12.98M 1.84M 13.06M
TNFA cash flow history

TNF Pharmaceuticals other data

Frequently Asked Questions (FAQ)

  • What's the price of TNF Pharmaceuticals stock today?

    One share of TNF Pharmaceuticals stock can currently be purchased for approximately $0.1.

  • When is TNF Pharmaceuticals's next earnings date?

    Unfortunately, TNF Pharmaceuticals's (TNFA) next earnings date is currently unknown.

  • Does TNF Pharmaceuticals pay dividends?

    No, TNF Pharmaceuticals does not pay dividends.

  • How much money does TNF Pharmaceuticals make?

    TNF Pharmaceuticals has a market capitalization of 3.71M.

  • What is TNF Pharmaceuticals's stock symbol?

    TNF Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "TNFA".

  • What is TNF Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of TNF Pharmaceuticals?

    Shares of TNF Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does TNF Pharmaceuticals have?

    TNF Pharmaceuticals, Inc. employs 6 workers.

  • What is TNF Pharmaceuticals's official website?

    The official website for TNF Pharmaceuticals is tnfpharma.com.

  • Where are TNF Pharmaceuticals's headquarters?

    TNF Pharmaceuticals is headquartered at 855 N. Wolfe Street, Baltimore, MD.

  • How can i contact TNF Pharmaceuticals?

    TNF Pharmaceuticals's mailing address is 855 N. Wolfe Street, Baltimore, MD and company can be reached via phone at +856 8488698.

TNF Pharmaceuticals company profile:

TNF Pharmaceuticals, Inc.

tnfpharma.com
Exchange:

NASDAQ

Full time employees:

6

Industry:

Biotechnology

Sector:

Healthcare

TNF Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company. It focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. Its MYMD-1 is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. The MYMD-1 is being developed to delay aging, increase longevity, and treat autoimmune diseases. The company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, and epilepsy. The Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve the growing CBD market, which includes FDA approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in Baltimore, Maryland.

+856 8488698
855 N. Wolfe Street
Baltimore, MD 21205

:
ISIN: US62856X2018
: